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1. INTRODUCTION {#apt14794-sec-0005}
===============

Crohn\'s disease is a chronic inflammatory bowel disease characterised by granulomatous inflammation, most commonly involving the terminal ileum and colon. The onset is most frequently in the second to fourth decade with characteristic symptoms of abdominal pain, diarrhoea, and weight loss and potential systemic and extraintestinal complications. Most patients have alternating periods of relapse and remission with half of patients requiring surgery within 10 years of diagnosis. The approach to treatment has evolved from control of symptoms to preventing progression of the disease. Therefore, treatments that safely maintain long‐term remission are essential.[1](#apt14794-bib-0001){ref-type="ref"}

Treatment guidelines for Crohn\'s disease recommend maintenance therapy after remission is achieved, particularly for moderate‐to‐high risk patients.[2](#apt14794-bib-0002){ref-type="ref"} Potential benefits include reduction in hospitalisation and surgery and improved quality of life.[3](#apt14794-bib-0003){ref-type="ref"}, [4](#apt14794-bib-0004){ref-type="ref"} Long‐term efficacy has been demonstrated with azathioprine/mercaptopurine,[5](#apt14794-bib-0005){ref-type="ref"} methotrexate,[6](#apt14794-bib-0006){ref-type="ref"} tumour necrosis factor (TNF) antagonists,[7](#apt14794-bib-0007){ref-type="ref"}, [8](#apt14794-bib-0008){ref-type="ref"}, [9](#apt14794-bib-0009){ref-type="ref"}, [10](#apt14794-bib-0010){ref-type="ref"}, [11](#apt14794-bib-0011){ref-type="ref"} natalizumab,[12](#apt14794-bib-0012){ref-type="ref"} and vedolizumab.[13](#apt14794-bib-0013){ref-type="ref"} Although TNF antagonists have significantly advanced the care of Crohn\'s disease, their efficacy is limited[14](#apt14794-bib-0014){ref-type="ref"} and the development of anti‐drug antibodies is associated with loss of response.[15](#apt14794-bib-0015){ref-type="ref"}, [16](#apt14794-bib-0016){ref-type="ref"}, [17](#apt14794-bib-0017){ref-type="ref"} In addition, potential significant side effects of maintenance treatments include bone marrow suppression,[18](#apt14794-bib-0018){ref-type="ref"} malignancy,[19](#apt14794-bib-0019){ref-type="ref"}, [20](#apt14794-bib-0020){ref-type="ref"} and serious infections.[21](#apt14794-bib-0021){ref-type="ref"}, [22](#apt14794-bib-0022){ref-type="ref"} Therefore, a need exists for safer agents that have demonstrated improved long‐term maintenance efficacy.

Ustekinumab is a monoclonal antibody to the p40 subunit of interleukin‐12 and interleukin‐23 that has been approved for use in the treatment of psoriasis, psoriatic arthritis, and Crohn\'s disease.[23](#apt14794-bib-0023){ref-type="ref"} Both clinical trial and registry data have confirmed the positive long‐term efficacy and safety profile of ustekinumab in psoriasis.[24](#apt14794-bib-0024){ref-type="ref"}, [25](#apt14794-bib-0025){ref-type="ref"}, [26](#apt14794-bib-0026){ref-type="ref"} The efficacy and safety of ustekinumab in Crohn\'s disease through 1 year has been previously established in the UNITI‐1 and UNITI‐2 (8 weeks) and IM‐UNITI (44 weeks) studies in patients who have failed TNF antagonists or conventional therapies (predominantly regimens excluding anti‐TNF medications).[27](#apt14794-bib-0027){ref-type="ref"} Here, we report the IM‐UNITI long‐term extension data demonstrating the maintenance of response and remission (Week 92) with a positive safety profile (Week 96).

2. METHODS {#apt14794-sec-0006}
==========

2.1. Study design and endpoints {#apt14794-sec-0007}
-------------------------------

IM‐UNITI is a continuing Phase 3 ustekinumab maintenance study in patients with Crohn\'s disease. The Phase 3 programme included two 8‐week, identically designed, induction studies (UNITI‐1 and UNITI‐2) with distinct populations and one maintenance study (Figure [1](#apt14794-fig-0001){ref-type="fig"}). The detailed study designs, eligibility criteria, and results for the UNITI and IM‐UNITI studies through Week 44 have been previously published.[27](#apt14794-bib-0027){ref-type="ref"} Briefly, UNITI‐1 patients were required to have received one or more TNF antagonists at approved doses and to have met the criteria for primary nonresponse (the absence of a response), secondary nonresponse (a response that was not maintained), or to have had unacceptable side effects to TNF antagonists. UNITI‐2 patients were required to have failed (including unacceptable side effects) conventional therapy (steroids or immunomodulators \[mercaptopurine, azathioprine or methotrexate\]), but had not previously failed TNF antagonists. Induction study patients were eligible to enrol in IM‐UNITI.

![Study design for IM‐UNITI phase 3 Crohn\'s disease program\*. R, randomisation; IV, intravenous; SC, subcutaneous; q8w, every 8 weeks; q12w, every 12 weeks; PE, primary endpoint; LTE, long‐term extension; DBL, database lock. \*Unblinding occurred when the final patients reached Week 44](APT-48-65-g001){#apt14794-fig-0001}

The primary population (randomised) for IM‐UNITI comprised 397 patients from UNITI‐1 or UNITI‐2 who were in clinical response at Week 8 after ustekinumab intravenous induction, defined as a reduction from baseline in Crohn\'s Disease Activity Index (CDAI) of ≥100 points or being in remission. These patients were randomly assigned, in a 1:1:1 ratio, to receive subcutaneous injections of 90 mg of ustekinumab every 8 weeks, 90 mg of ustekinumab every 12 weeks, or placebo through Week 40 with a Week 44 primary endpoint of clinical remission, defined as a CDAI score of \<150 points. Randomised patients who subsequently met loss of response criteria at any time between Week 8 and Week 32 were eligible to have a single dose adjustment to ustekinumab 90 mg every 8 weeks; these patients were evaluated 16 weeks after dose adjustment and were discontinued from ustekinumab if not clinically improved.

The remainder of UNITI‐1 or UNITI‐2 patients could continue in IM‐UNITI but were not randomised and were treated as follows: Placebo induction responders continued placebo and placebo nonresponders received intravenous ustekinumab 130 mg at IM‐UNITI Week 0, and continued subcutaneous ustekinumab 90 mg every 12 weeks if in clinical response at Week 8. Intravenous ustekinumab induction nonresponders received subcutaneous ustekinumab 90 mg at IM‐UNITI Week 0 and continued ustekinumab 90 mg every 8 weeks if in clinical response at Week 8.

All patients (randomised and nonrandomised) who completed the safety and efficacy evaluation at Week 44 were eligible to participate in the IM‐UNITI extension, based upon the investigator\'s opinion that they would benefit from continued treatment. Throughout the extension, patients continued to receive the same treatment regimen that they were receiving at Week 44, without any further dose adjustment. The IM‐UNITI study was unblinded when the last patient in the main study completed the Week 44 evaluations and the Week 44 analyses were completed.

Efficacy was assessed through Week 92, with clinical remission defined as a CDAI score of \<150 points and clinical response defined as a reduction from Week 0 of UNITI‐1 or UNITI‐2 in the CDAI score of ≥100 points (or if a CDAI score of \<150 was attained). Corticosteroid‐free remission was defined as a CDAI score of \<150 points without receiving corticosteroids at Week 92. Additional efficacy evaluations in the IM‐UNITI long‐term extension included CDAI and serum C‐reactive protein (CRP) every 12 weeks until Week 44 unblinding and then at every dosing visit, and the Inflammatory Bowel Disease questionnaire (IBDQ) and the 36‐Item Short Form Survey (SF‐36) every 6 months. Safety was assessed every 4 weeks through Week 96.

Patients were evaluated for antibodies to ustekinumab every 6 months. Analyses of antibodies to ustekinumab were performed using a validated, drug‐tolerant electro‐chemiluminescence immunoassay, in which ustekinumab was used to capture and detect induced immune responses to ustekinumab. Janssen or its designee assayed these samples, under conditions in which the identification of the patient and treatment assignment was blinded.

2.2. Statistical analysis {#apt14794-sec-0008}
-------------------------

Because placebo patients discontinued the study after treatment assignments were unblinded to investigative sites (after the last patient completed Week 44 and database lock and subsequent analyses were completed), direct comparisons and/or statistical comparisons of efficacy results between placebo and ustekinumab treatment groups throughout the extension were not possible.

Demographic and baseline disease characteristics, efficacy and safety analyses were based on all patients treated with at least 1 administration of study agent during the long‐term extension. Descriptive statistics (eg, mean, median, standard deviation, interquartile range, minimum and maximum) were used to summarise continuous variables. Counts and percentages were used to summarise categorical variables.

For the IM‐UNITI long‐term extension, three types of analyses were conducted for remission data. Details of these analyses and the populations included are described in Table [1](#apt14794-tbl-0001){ref-type="table"}. In brief, they include (1) Analysis of patients who entered the long‐term extension, (2) Observed case analysis with inclusion only of patients who entered the long‐term extension who have data at that visit, (3) Analysis of all randomised patients in maintenance, regardless of whether they entered the long‐term extension.

###### 

Analyses for IM‐UNITI Long‐term Extension

  Analysis type                                                                                           Population included
  ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analyses of patients who entered the long‐term extension, over first year of long‐term extension        Pre‐specified analysisEvaluates clinical efficacy during the first year of the long‐term extension (ie, second year of treatment, from Week 44 to 92)Includes two analyses:1`o`Intravenous ustekinumab induction responders randomised in IM‐UNITI who entered the long‐term extension2`o`All patients who entered the long‐term extension2Patients who met a treatment failure criterion after Week 44 were considered to not be in remission at efficacy visits from the point of treatment failure through Week 92Patients who had insufficient data to calculate the CDAI score were considered not to be in remission at that visitPatients without corticosteroid information at Week 92 had the last available corticosteroid dose carried forward to Week 92
  Observed case analysis of randomised patients who entered the long‐term extension                       Pre‐specified analysisPatients who did not have data at a visit were excluded from analysis for that visitEvaluates rates of remission observed during the first year of the long‐term extension (Week 44 to Week 92) in intravenous ustekinumab induction responders randomised in IM‐UNITI who entered the long‐term extension and remained on treatment at that specific timepointThe same treatment failure rules as described in \#1 above were applied
  ITT analysis of randomised patients from Week 0 of maintenance[a](#apt14794-note-0006){ref-type="fn"}   Post‐hoc analysisEvaluates rates of remission through Week 92 among all intravenous ustekinumab induction responders originally randomised in IM‐UNITIConservative assessment of 92 week clinical efficacy, as patients who did not enter the long‐term extension or discontinued were considered to not be in remissionPatients who met any treatment failure criterion before or after Week 44 were considered not to be in remission from that point onwardPatients who had insufficient data to calculate the CDAI score were considered not to be in remission at that visit

ITT, intent‐to‐treat; CDAI, Crohn\'s disease activity index.

The efficacy population included 388 patients (excluding 9 patients enrolled prior to study restart who had received a prior investigational intravenous formulation in induction)

John Wiley & Sons, Ltd

For all efficacy analyses other than the observed case analysis, patients who had a Crohn\'s disease‐related surgery or discontinued study agent due to lack of efficacy or an adverse event indicated to be worsening Crohn\'s disease after Week 44 and prior to the designated analysis time point were considered not to be in clinical remission/response, regardless of their CDAI score. Patients with insufficient data to calculate the CDAI score at the designated analysis time point were considered not to be in clinical remission/response. Other dichotomous endpoints followed the same treatment failure and missing data rules.

For continuous endpoints, patients meeting these treatment failure rules prior to the designated analysis time point had their induction baseline value carried forward and if there was insufficient data to calculate the variable at the designated analysis time points their last value was carried forward.

The incidence of antibodies to ustekinumab were summarised for all treated patients who entered the long‐term extension and received at least 1 administration of ustekinumab, either in the induction studies or in this study, and had appropriate samples for detection of antibodies to ustekinumab (ie, patients with at least 1 sample obtained after their first dose of ustekinumab). Patients were considered positive even if antibodies were detected at any single timepoint. The relationships between antibody to ustekinumab status at Week 92 and clinical response and remission status, as well as injection‐site reactions at Week 92 were explored.

3. RESULTS {#apt14794-sec-0009}
==========

A total of 718 patients continued into the IM‐UNITI long‐term extension, of which 567 patients were treated with subcutaneous ustekinumab 90 mg every 12 weeks (n = 213) or every 8 weeks (n = 354). The other 151 patients received subcutaneous placebo (Figure [S1](#apt14794-sup-0001){ref-type="supplementary-material"}). Of the patients continuing to the long‐term extension, 84, 153 (71 with prior dose adjustment), and 61 patients on every 12 weeks, every 8 weeks, and placebo, respectively, had been in the primary population, representing approximately 75% (298/397) of the original randomised, primary population patients.

The clinical disease characteristics at Week 0 of UNITI‐1 and UNITI‐2 and at Week 0 of IM‐UNITI for randomised patients in the long‐term extension were generally similar among treatment groups and representative of a population with moderately to severely active Crohn\'s disease.[27](#apt14794-bib-0027){ref-type="ref"} As they entered the long‐term extension (Week 44 of IM‐UNITI), clinical disease characteristics of randomised patients were generally similar for ustekinumab 90 mg subcutaneous every 12 weeks and every 8 weeks groups and numerically higher (eg, CDAI scores, CRP concentrations) or lower (eg, IBDQ, patients in remission) for patients with prior dose adjustment (Table [2](#apt14794-tbl-0002){ref-type="table"}).

###### 

Disease characteristics of randomised patients who entered long‐term extension (at Week 44)

                                   Placebo   Continuous UST SC 90 mg q12w   Continuous UST SC 90 mg q8w   Patients with Prior Dose Adjustment[a](#apt14794-note-0008){ref-type="fn"}
  -------------------------------- --------- ------------------------------ ----------------------------- ----------------------------------------------------------------------------
  N                                61        84                             82                            71
  Median CDAI                      96.0      95.5                           70.5                          130.0
  Median IBDQ                      180.5     189.0                          185.5                         171.0
  Median CRP (mg/L)                6.7       3.5                            3.7                           4.0
  Patients in clinical remission   77.0%     77.4%                          84.1%                         63.4%

SC, subcutaneous; UST, ustekinumab; CDAI, Crohn\'s disease activity index; IBDQ, inflammatory bowel disease questionnaire; CRP, C‐reactive protein; q12w, every 12 weeks; q8w, every 8 weeks.

Patients who were in clinical response to UST induction dosing, were randomised, met loss of clinical response criteria from Week 8 through Week 32, and received UST 90 mg SC q8w (this includes patients who were randomised to 90 mg SC q8w who had a sham dose adjustment).

John Wiley & Sons, Ltd

Of the 298 randomised patients who were treated in the long‐term extension, 76/298 (25.5%) discontinued study agent from Week 44 through Week 96 (35/61 \[57%\] and 41/237 \[17.3%\] in the placebo and all ustekinumab 90 mg subcutaneous groups, respectively).

All patients remained blinded from Week 44 through Week 96 in the long‐term extension until the study unblinding, which occurred after completion of the Week 44 evaluations and analyses.

3.1. Randomised patients entering long‐term extension {#apt14794-sec-0010}
-----------------------------------------------------

### 3.1.1. Clinical remission Weeks 44‐92 {#apt14794-sec-0011}

The proportions of patients in clinical remission were generally maintained from Week 44 through Week 92 in the ustekinumab 90 mg every 12 weeks group (65/84 \[77.4%\] to 61/84 \[72.6%\]), and in the every 8 weeks group (69/82 \[84.1%\] to 61/82 \[74.4%\], respectively; Figure [2](#apt14794-fig-0002){ref-type="fig"}A). At Week 92, the proportions of patients in clinical remission were similar in the ustekinumab 90 mg every 12 weeks (61/84 \[72.6%\]) and every 8 weeks (61/82 \[74.4%\]) groups and lower in patients with prior dose adjustment (38/71 \[53.5%\]; Table [3](#apt14794-tbl-0003){ref-type="table"}).

![Clinical remission from Week 44 through Week 92 of treatment among (A) all randomised patients entering the long‐term extension and (B) by induction study subgroups. SC, subcutaneous; TNF, tumour necrosis factor; q8w, every 8 weeks; q12w, every 12 weeks](APT-48-65-g002){#apt14794-fig-0002}

###### 

IM‐UNITI efficacy assessments at Week 92 among randomised patients who entered long‐term extension[a](#apt14794-note-0010){ref-type="fn"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                       All Patients   UNITI‐1        UNITI‐2                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  N                                                                                                                    84             82             71             32             27             32             59             52             55             39             94

  Clinical Remission (%)                                                                                               72.6           74.4           53.5           59.4           70.4           46.9           57.6           80.8           76.4           59.0           69.1

  Clinical response (%)                                                                                                83.3           80.5           67.6           68.8           81.5           56.3           67.8           92.3           80.0           76.9           78.7

  Clinical remission and not receiving corticosteroids (%)                                                             67.9           63.4           42.3           56.3           59.3           31.3           44.1           75.0           65.5           51.3           59.6

  Clinical remission in UNITI‐1\                                                                                       19/32 (59.4)   19/27 (70.4)   15/32 (46.9)   19/32 (59.4)   19/27 (70.4)   15/32 (46.9)   34/59 (57.6)                                                 
  subset N (%)[c](#apt14794-note-0012){ref-type="fn"}                                                                                                                                                                                                                        

  Clinical remission in the UNITI‐2 subset patients naive to TNF antagonists[d](#apt14794-note-0013){ref-type="fn"}\   29/38 (76.3)   29/39 (74.4)   18/28 (64.3)                                                               29/38 (76.3)   29/39 (74.4)   18/28 (64.3)   47/67 (70.1)
  N (%)                                                                                                                                                                                                                                                                      

  Median change in CDAI from maintenance baseline[e](#apt14794-note-0014){ref-type="fn"}                               −34.0          −40.0          −24.0          −21.0          −49.0          11.0           −33.0          −51.5          −40.0          −27.0          −37.5
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SC, subcutaneous; UST, ustekinumab; CDAI, Crohn\'s disease activity index; q12w, every 12 weeks; q8w, every 8 weeks; Pts, patients; TNF, tumour necrosis factor.

Patients who had insufficient data at Week 92 are considered not to be in clinical remission or response.

Patients who were in clinical response to ustekinumab induction dosing, were randomised, met loss of response criteria from Week 8 through Week 32 and received 90 mg SC q8w (this includes patients who were randomised to 90 mg SC q8w who had a sham dose adjustment).

Patients refractory or intolerant to TNF antagonists (UNITI‐1).

Patients naive to TNF antagonists from UNITI‐2.

Patients who had insufficient data to calculate the CDAI score at Week 92 had their last value carried forward.

John Wiley & Sons, Ltd

### 3.1.2. Clinical remission by induction study, Weeks 44‐92 {#apt14794-sec-0012}

The proportions of patients in clinical remission were generally maintained from Week 44 through Week 92 for patients from both the UNITI‐1 and UNITI‐2 populations (Figure [2](#apt14794-fig-0002){ref-type="fig"}B).

The proportions of UNITI‐1 patients in clinical remission at Week 92 were 19/32 (59.4%) in the ustekinumab 90 mg every 12 weeks group, 19/27 (70.4%) in the every 8 weeks group and 15/32 (46.9%) for patients with prior dose adjustment (Table [3](#apt14794-tbl-0003){ref-type="table"}).

At Week 92, the proportions of UNITI‐2 patients in clinical remission were 42/52 (80.8%) in the ustekinumab 90 mg every 12 weeks group, 42/55 (76.4%) in the every 8 weeks group and 23/39 (59.0%) in patients with prior dose adjustment. In the subset of patients who were TNF antagonist‐naïve, data were generally consistent with the overall UNITI‐2 population (Table [3](#apt14794-tbl-0003){ref-type="table"}).

### 3.1.3. Corticosteroid‐free remission {#apt14794-sec-0013}

The proportions of patients in clinical remission at Week 92 and not receiving corticosteroids at Week 92 were similar in the ustekinumab 90 mg every 12 weeks (57/84; 67.9%) and every 8 weeks (52/82; 63.4%) groups and were lower in patients with prior dose adjustment (30/71; 42.3%; Table [3](#apt14794-tbl-0003){ref-type="table"}).

### 3.1.4. Clinical response {#apt14794-sec-0014}

At Week 92, the proportions of patients in clinical response were similar for patients in the ustekinumab 90 mg every 12 weeks (83.3%) and every 8 weeks (80.5%) groups and lower in patients with prior dose‐adjustment (67.6%) (Table [3](#apt14794-tbl-0003){ref-type="table"}).

### 3.1.5. Change in CDAI over time from maintenance baseline {#apt14794-sec-0015}

The median change from maintenance baseline in CDAI scores for randomised patients at Week 92 was −34.0 in the ustekinumab 90 mg every 12 weeks group, −40.0 in the every 8 weeks group, and −24.0 in patients with prior dose adjustment (Table* * [3](#apt14794-tbl-0003){ref-type="table"}).

### 3.1.6. Patients with normalised CRP {#apt14794-sec-0016}

The proportions of randomised patients with normalised CRP levels were generally stable from Week 44 through Week 92 in both the ustekinumab 90 mg every 12 weeks (36.1% to 29.5%) and every 8 weeks (30.4% to 26.8%) groups (Figure* * [3](#apt14794-fig-0003){ref-type="fig"}).

![Proportions of patients with normalised CRP (≥3 mg/L) from Week 44 through Week 92; randomised patients who entered the long‐term extension. CRP, C‐reactive protein; SC, subcutaneous; q8w, every 8 weeks; q12w, every 12 weeks](APT-48-65-g003){#apt14794-fig-0003}

### 3.1.7. Patient reported outcomes {#apt14794-sec-0017}

#### IBDQ {#apt14794-sec-0018}

At Week 0 of IM‐UNITI, the median IBDQ total score, IBDQ dimension (bowel, emotional, systemic, and social) scores were similar across treatment groups (Table* * [4](#apt14794-tbl-0004){ref-type="table"}). The proportions of patients with at least a 16‐point improvement in IBDQ score from baseline of the induction study were similar at Week 92 for patients in the ustekinumab 90 mg every 12 weeks (73.8%) and every 8 weeks group (76.8%), and lower in patients with prior dose adjustment (62.0%; Table [4](#apt14794-tbl-0004){ref-type="table"}).

###### 

Inflammatory bowel disease questionnaire (IBDQ) and 36‐item short form survey (SF‐36) scores at baseline, Week 44, and Week 92

                                                   Continuous SC UST 90 mg q12w   Continuous SC UST 90 mg q8w   Patients with Prior Dose Adjustment[a](#apt14794-note-0017){ref-type="fn"}   All UST treated
  ------------------------------------------------ ------------------------------ ----------------------------- ---------------------------------------------------------------------------- -----------------
  **IBDQ**                                                                                                                                                                                   
  N                                                84                             82                            71                                                                           237
  Median baseline score                            175.0                          179.0                         175.0                                                                        178.0
  Median change from baseline at Week 44           8.0                            5.0                           −1.0                                                                         5.0
  Median change from baseline at Week 92           3.5                            9.0                           6.0                                                                          6.0
  Patients with ≥16‐point improvement at Week 92   73.8%                          76.8%                         62.0%                                                                        71.3%
  Bowel                                                                                                                                                                                      
  N                                                84                             82                            71                                                                           237
  Median baseline score                            57.0                           57.5                          54.0                                                                         56.0
  Median change from baseline at Week 92           1.0                            3.0                           2.0                                                                          2.0
  Emotional                                                                                                                                                                                  
  N                                                84                             82                            71                                                                           237
  Median baseline score                            65.5                           66.0                          64.0                                                                         66.0
  Median change from baseline at Week 92           1.5                            4.0                           1.0                                                                          2.0
  Systemic                                                                                                                                                                                   
  N                                                84                             82                            71                                                                           237
  Median baseline score                            24.0                           25.0                          25.0                                                                         25.0
  Median change from baseline at Week 92           1.0                            2.0                           0.0                                                                          1.0
  Social                                                                                                                                                                                     
  N                                                84                             81                            71                                                                           236
  Median baseline score                            31.0                           31.0                          30.0                                                                         31.0
  Median change from baseline at Week 92           1.0                            1.0                           0.0                                                                          1.0
  **SF‐36**                                                                                                                                                                                  
  PCS                                                                                                                                                                                        
  N                                                76                             75                            69                                                                           220
  Median baseline score                            49.50                          50.12                         48.36                                                                        49.54
  Median change from baseline at Week 44           1.92                           0.88                          0.31                                                                         0.96
  Median change from baseline at Week 92           1.21                           2.93                          0.81                                                                         2.02
  Patients with a 5‐point improvement at Week 92   59.2%                          69.3%                         59.4%                                                                        62.7%
  MCS                                                                                                                                                                                        
  N                                                76                             75                            69                                                                           220
  Median baseline score                            48.69                          49.43                         49.95                                                                        49.38
  Median change from baseline at Week 44           3.34                           2.00                          −0.04                                                                        1.79
  Median change from baseline at Week 92           2.80                           2.51                          −1.68                                                                        0.89
  Patients with a 5‐point improvement at Week 92   65.8%                          62.7%                         49.3%                                                                        59.5%

SC, subcutaneous; UST, ustekinumab; q12w, every 12 weeks; q8w, every 8 weeks; PCS, Physical Component score; MCS, Mental Component score.

Patients who were in clinical response to ustekinumab (UST) induction dosing, were randomised, met loss of response criteria from Week 8 through Week 32 and received 90 mg SC q8w (this includes patients who were randomised to 90 mg SC q8w who had a sham dose adjustment).
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The median change from maintenance baseline in IBDQ scores was higher at Week 92 for patients in the ustekinumab 90 mg every 8 weeks group (9.0) as compared with patients in the every 12 weeks group (3.5), and those patients with prior dose adjustment (6.0). The median changes from maintenance baseline in IBDQ dimension scores (eg, bowel, emotional, systemic, and social) were generally higher for the ustekinumab 90 mg every 12 weeks and every 8 weeks groups as compared with the prior dose adjustment group.

#### SF‐36 {#apt14794-sec-0019}

The median SF‐36 scores at Week 0 of IM‐UNITI were similar across treatment groups (Table [4](#apt14794-tbl-0004){ref-type="table"}). At Week 92, comparable results were observed among these groups in the proportion of patients with at least a five‐point improvement in both the SF‐36 physical and mental component scores (Table [4](#apt14794-tbl-0004){ref-type="table"}).

3.2. All treated patients entering long‐term extension {#apt14794-sec-0020}
------------------------------------------------------

### 3.2.1. Remission and response Weeks 44‐92 {#apt14794-sec-0021}

From Week 44 to Week 92, the proportions of patients in clinical remission remained similar in the every 12 weeks (68.5% to 64.3%; n = 213) and the every 8 weeks groups (68.9% to 64.4%; n = 354, data not shown).

In these same groups, from Week 44 to 92, the proportions of patients in clinical response remained similar in both the every 12 weeks (86.9% to 79.3%; n = 213) and the every 8 weeks groups (89.0% to 75.7%; n = 354).

3.3. Observed case analysis of randomised patients entering long‐term extension {#apt14794-sec-0022}
-------------------------------------------------------------------------------

Using observed data, clinical remission rates were also maintained from Week 44 through Week 92 in the ustekinumab 90 mg every 12 weeks group (77.4%‐79.2%), as well as in the every 8 weeks group (84.1%‐87.1%; Figure [4](#apt14794-fig-0004){ref-type="fig"}).

![Patients in clinical remission from Week 44 through Week 92 of IM‐UNITI long‐term extension: observed data](APT-48-65-g004){#apt14794-fig-0004}

3.4. Intent‐to‐treat analysis of randomised patients from Week 0 of maintenance {#apt14794-sec-0023}
-------------------------------------------------------------------------------

Of patients originally randomised to ustekinumab 90 mg every 12 weeks, 45.0% (58/129) were in remission at Week 92, and 46.9% (60/128) of patients originally randomised to 90 mg every 8 weeks were in remission at Week 92, including 55.8% (29/52) of patients in the TNF‐antagonist naïve subset. Consistent with other analyses, remission rates were sustained from Week 44 through Week 92 (Figure [5](#apt14794-fig-0005){ref-type="fig"}).

![Long‐term rates of remission for patients responding to ustekinumab induction through Week 92 (intent‐to‐treat analysis of IM‐UNITI primary population from Week 0). SC, subcutaneous; q8w, every 8 weeks; q12w, every 12 weeks](APT-48-65-g005){#apt14794-fig-0005}

3.5. Safety in all treated patients entering long‐term extension {#apt14794-sec-0024}
----------------------------------------------------------------

### 3.5.1. Weeks 0‐96 {#apt14794-sec-0025}

Safety events (per hundred patient‐years) were similar among all ustekinumab‐treated patients compared to placebo, including overall adverse events (484.39 vs 447.76), serious adverse events (19.24 vs 18.82), and serious infections (4.09 vs 4.02), with 244.2 patient‐years of follow‐up among placebo‐treated patients and 1020.0 patient‐years years among all ustekinumab‐treated patients. The number of adverse events, serious adverse events, and serious infections per hundred patient‐years were generally comparable for the ustekinumab 90 mg every 12 weeks and every 8 weeks groups***,*** without dose effect (Table [5](#apt14794-tbl-0005){ref-type="table"}).

###### 

Summary of key safety finding per hundred patient‐years of follow‐up from Week 0 through Week 96: all patients who entered long‐term extension[a](#apt14794-note-0019){ref-type="fn"}

                                                                                                Placebo                   SC UST 90 mg q12w                          SC UST 90 mg q8w          All UST
  --------------------------------------------------------------------------------------------- ------------------------- ------------------------------------------ ------------------------- -------------------------
  **N**                                                                                         151                       213                                        354                       567
  Average duration of follow‐up (weeks)                                                         84.1                      93.8                                       93.4                      93.5
  Total patient‐years of follow‐up                                                              244.2                     384.3                                      635.6                     1020.0
  Deaths                                                                                        0                         1[b](#apt14794-note-0020){ref-type="fn"}   2                         3
  Number of specified events per hundred patient‐years of follow‐up (95% confidence interval)                                                                                                  
  Adverse events                                                                                484.39 (457.18, 512.80)   413.70 (393.62, 434.55)                    468.36 (451.68, 485.49)   447.76 (434.87, 460.94)
  Serious adverse events                                                                        19.24 (14.14, 25.59)      19.51 (15.35, 24.46)                       18.41 (15.22, 22.06)      18.82 (16.26, 21.68)
  Infections                                                                                    105.64 (93.14, 119.35)    112.66 (102.30, 123.79)                    120.51 (112.13, 129.36)   117.55 (110.99, 124.40)
  Serious infections                                                                            4.09 (1.96, 7.53)         5.72 (3.59, 8.67)                          2.99 (1.80, 4.67)         4.02 (2.88, 5.45)

SC, subcutaneous; UST, ustekinumab; q12w, every 12 weeks; q8w, every 8 weeks

Data are based on all randomised and nonrandomised patients combined by regimen who entered the long‐term extension

Death occurred in a nonrandomised patient on q12w UST after withdrawal of consent

John Wiley & Sons, Ltd

### 3.5.2. Weeks 44‐96 {#apt14794-sec-0026}

Safety events (per hundred patient‐years) were similar among all ustekinumab‐treated patients compared to placebo, including overall adverse events (401.27 vs 371.84), serious adverse events (24.27 vs 19.56), and serious infections (5.20 vs 3.73), with 115.4 patient‐years of follow‐up among placebo‐treated patients and 536.8 patient‐years years among all ustekinumab‐treated patients. No dose effect was seen.

One case of tuberculosis deemed unrelated to study drug by the investigator was reported in a 45‐year‐old male from South Africa who received ustekinumab every 8 weeks during the long‐term extension. Although negative for tuberculosis during screening at study entry and asymptomatic, the patient had a positive QuantiFERON‐TB Gold test on routine annual screening and had bronchial brushings that were positive for mycobacterium tuberculosis. The patient completed 6 months of therapy for tuberculosis with complete resolution. A single, serious opportunistic infection of cytomegalovirus colitis occurred in a 32‐year old who received ustekinumab induction followed by placebo maintenance (440 days after last exposure to ustekinumab). The patient was treated with ganciclovir with resolution of the infection.

The number of treatment‐emergent malignancies per hundred patient‐years of follow‐up was 2.60 for placebo patients, and 0.37 for ustekinumab patients. Five malignancies were reported in patients during the long‐term extension. One squamous cell cutaneous carcinoma in a patient randomised in maintenance to placebo and who continued to receive placebo in the long‐term extension; one testicular seminoma in a 31‐year‐old male randomised in maintenance to ustekinumab 90 mg subcutaneous every 8 weeks; and one basal cell carcinoma in a patient who was not randomised but received ustekinumab 90 mg subcutaneous every 12 weeks during the long‐term extension. Two malignancies (papillary thyroid cancer and squamous cell cutaneous carcinoma) were reported in two patients who were not randomised and did not receive ustekinumab throughout the entire study.

Three deaths were reported, two of presumed cardiovascular causes and one suicide. Two of the three patients received ustekinumab 90 mg every 8 weeks and one patient received ustekinumab 90 mg every 12 weeks.

The proportions of patients with 1 or more injection‐site reactions was 2.0% (n = 11) for ustekinumab patients and 0.6% (n = 6) for placebo patients with no reports of serious reactions, anaphylaxis or serum sickness‐like reactions.

3.6. Immunogenicity in randomised patients entering long‐term extension {#apt14794-sec-0027}
-----------------------------------------------------------------------

A total of 237 randomised patients who received ustekinumab during the long‐term extension had appropriate samples for antibody to ustekinumab status through Week 96. Across all randomised treatment groups, 4.2% (10/237) of ustekinumab subcutaneous‐treated patients were positive for antibodies to ustekinumab. Among patients on continuous 90 mg every 8 weeks treatment, the rate of antibodies to ustekinumab was 2.4%, similar to the rate seen in this group at 44 weeks.[27](#apt14794-bib-0027){ref-type="ref"} Of note, rates of antibodies to ustekinumab were higher among patients who were randomised to placebo (8.2%; 5/61).

4. DISCUSSION {#apt14794-sec-0028}
=============

IM‐UNITI is the 5‐year maintenance study in the Phase 3 pivotal programme for treatment of patients with Crohn\'s disease with ustekinumab. As previously shown, through 44 weeks of treatment, statistically significant evidence was generated demonstrating that treatment with subcutaneous ustekinumab 90 mg every 12 weeks or every 8 weeks was effective in maintaining clinical response and remission in patients with moderate‐to‐severe Crohn\'s disease.[27](#apt14794-bib-0027){ref-type="ref"}

Our findings confirm that in ustekinumab induction responders, remission, and response rates were maintained through Week 92 of the study in both TNF antagonist‐refractory patients from UNITI‐1 and UNITI‐2 conventional therapy failure patients (predominantly TNF antagonist‐naïve). However, maintenance of remission from Week 44 to Week 92 of subcutaneous ustekinumab was slightly lower in the UNITI‐1 subset. Efficacy from Week 44 to Week 92 of subcutaneous ustekinumab maintenance in patients entering the long‐term extension was similar for both the every 8 weeks and every 12 weeks subcutaneous ustekinumab dose regimens, in both populations. In a combined analysis that included all randomised treatment groups, patients who had previously met loss of response criteria for dose adjustment before Week 44 had somewhat lower remission rates over the second year of treatment. Similar and consistent efficacy was observed for every 12 weeks and every 8 weeks dosing as measured by proportions of patients with normalised CRP and in those experiencing improvements in IBDQ and SF‐36 health‐related quality of life. Discontinuation rates were low, with over 90% of all patients completing Week 96 of the extension trial.

Many controlled maintenance studies of biological agents have been limited to 1 year or less in duration,[7](#apt14794-bib-0007){ref-type="ref"}, [8](#apt14794-bib-0008){ref-type="ref"}, [11](#apt14794-bib-0011){ref-type="ref"}, [12](#apt14794-bib-0012){ref-type="ref"} with the exceptions of adalimumab and vedolizumab.[9](#apt14794-bib-0009){ref-type="ref"}, [10](#apt14794-bib-0010){ref-type="ref"}, [13](#apt14794-bib-0013){ref-type="ref"} Recognising the challenges of cross‐study comparisons, due to differences in study populations, efficacy measures, statistical analysis, and study designs, it is difficult to compare these results with previous adalimumab or vedolizumab long‐term extension data. However, the maintenance of efficacy with ustekinumab in patients with Crohn\'s disease was stable over 92 weeks of treatment. This experience of ustekinumab in patients with Crohn\'s disease is consistent with that seen with maintenance of efficacy and excellent retention through 5 years reported from the ustekinumab psoriasis Phase 3 studies[28](#apt14794-bib-0028){ref-type="ref"}, [29](#apt14794-bib-0029){ref-type="ref"} and superior ustekinumab drug survival rates compared to TNF antagonists in the large psoriasis PSOLAR registry.[26](#apt14794-bib-0026){ref-type="ref"}

Variability in efficacy from Weeks 44 to 92 of the long‐term extension was seen, depending on the analysis and the treatment group. Not unexpectedly, remission rates were higher with an as‐observed analysis. Remission rates were lower if all responders who entered IM‐UNITI were included in the analysis as opposed to only those who entered the long‐term extension. However, even with this most stringent analysis, remission rates remained stable in the study, with the clinically important observation that, even when analysed in this conservative fashion, approximately one‐half of induction responders were in remission at Week 92. These results are consistent with a recently published retrospective multicentre cohort study of 122 refractory Crohn\'s disease patients who were treated with ustekinumab with a median follow‐up of 26.6 months.[30](#apt14794-bib-0030){ref-type="ref"}

In general, patients who had not failed an anti‐TNF therapy (UNITI‐2) demonstrated higher rates of remission at Week 92, consistent with the Week 44 results.[27](#apt14794-bib-0027){ref-type="ref"} While results were generally consistent between every 8 weeks and every 12 weeks treatment groups from Week 44 to Week 92, differences seen at Week 44 were generally sustained through Week 92. Clinical efficacy was consistently lower across endpoints for those patients who dose‐adjusted before entering the long‐term extension. Perhaps not surprisingly, upon entry into the long‐term extension, these patients (who had already previously met loss of response criteria prior to Week 44) had notably higher median CDAI scores, higher median CRP concentrations, lower median IBDQ scores, and lower rates of clinical remission, indicating that they are a subset with more severe disease. Among all treated patients (incorporating these patients as well as the nonrandomised and randomised groups), rates of response and remission were also slightly lower than the randomised every 8 weeks and every 12 weeks groups, but were similarly maintained. While some data have been published on predictors of response to ustekinumab in Crohn\'s disease patients, further analyses to identify patients who are most likely to achieve maximum benefit from ustekinumab would be helpful.[31](#apt14794-bib-0031){ref-type="ref"}

Rates of patients who developed anti‐drug antibodies were low and formation of antibodies did not impact response and remission rates. In randomised patients who received continuous treatment, the number of patients with anti‐drug antibodies remained low and was consistent from Week 44 through Week 96.[27](#apt14794-bib-0027){ref-type="ref"} Randomised patients who received an induction dose of ustekinumab followed by placebo had higher rates of antibodies, suggesting that drug exposure followed by a significant gap in treatment may increase the risk of antibody formation. However, even this proportion with antibodies (8%) is low compared to anti‐drug antibody rates seen with other approved Crohn\'s disease biologics,[32](#apt14794-bib-0032){ref-type="ref"} particularly when those drugs are assessed using similar high sensitivity, drug tolerant assays.

While patients in this long‐term extension were not subject to dose escalation based on drug concentrations, a previous analysis of ustekinumab serum concentrations of UNITI‐1, UNITI‐2 and through Week 44 of IM‐UNITI demonstrated a relationship between serum concentrations and efficacy.[33](#apt14794-bib-0033){ref-type="ref"} This supports the use of the every 8 weeks dose regimen or the option to dose escalate if patients who start every 12 weeks dosage fail to achieve response or lose response, as was allowed before Week 44 of IM‐UNITI. However, future studies are needed to evaluate whether proactive therapeutic drug monitoring of ustekinumab to target levels improves long‐term Crohn\'s disease outcomes. Of note, in contrast to TNF antagonists, in the previous study,[33](#apt14794-bib-0033){ref-type="ref"} there was no significant impact of co‐treatment with immunomodulators on serum concentrations, possibly related to the low immunogenicity of ustekinumab.

In the study extension through Week 96, ustekinumab was well‐tolerated with a favourable safety profile that did not differentiate from placebo. Among all treated patients, events per hundred patient‐years of adverse events, serious adverse events, and serious infections were similar among the every 12 weeks and every 8 weeks groups, individually, with no evidence of a dose effect. Between the two dose groups and among combined ustekinumab groups, there was no difference in the number of these events compared to placebo. No serious opportunistic infections occurred in ustekinumab‐treated patients from Week 44 to Week 96. A nonserious infection of pulmonary tuberculosis occurred in a patient living in a region endemic for tuberculosis and who received ustekinumab every 8 weeks during the study extension. Rates of injection‐site reactions remained low with no reports of serious reactions, anaphylaxis, or serum sickness‐like reactions. Rates of malignancy were not increased. Three deaths were reported during the study extension with an observed rate of death comparable to the rate of death in a large cohort study of patients with Crohn\'s disease.[34](#apt14794-bib-0034){ref-type="ref"}

There are limitations in the study extension design. First, patients were selected by the investigator to participate in the study extension because in their opinion, they might benefit from continued treatment (although 97.5% \[719/737\] of patients that reached Week 44 did so). This criterion may limit the generalisability of the findings to only those patients who responded to and tolerated ustekinumab through approximately 1 year of treatment. Second, because patients who entered the study extension on placebo represent a group of patients who were long‐term responders to ustekinumab induction or were true placebo responders and were therefore discontinued from the study when unblinding occurred, direct efficacy and statistical comparisons between placebo and ustekinumab treatment groups could not be performed over the long‐term extension duration. Hence, the emphasis of this manuscript is on efficacy measures among ustekinumab‐treated patients.

In summary, patients with moderately to severely active Crohn\'s disease, who received ustekinumab in the study extension, maintained clinical response and clinical remission through Week 92 of IM‐UNITI. Clinical results were supported by maintained normalisation of CRP concentrations and improved health‐related quality of life outcome measures. The safety profile observed for ustekinumab through Week 96 of treatment was consistent with the safety through Week 96 and with the established safety profile within the ustekinumab prescribing information with no new safety signals identified. Additional efficacy and safety data from IM‐UNITI will continue to be generated through 5 years of maintenance.
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